SCHEMBL9239194

SCHEMBL9239194

NNc1nc2ncccc2[nH]1

nearest known ligand 0.59

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
NUDT1 P36639 1/20 0.59
METAP1 P53582 2/20 0.49
METAP2 P50579 1/20 0.49
PDE5A O76074 3/20 0.45
AURKA O14965 6/20 0.44
HPSE Q9Y251 1/20 0.43
TP53 P04637 1/20 0.43
KDM4E B2RXH2 1/20 0.42
CYP1A2 P05177 1/20 0.42
MAPT P10636 1/20 0.42
CYP2C9 P11712 1/20 0.42
CYP2C19 P33261 1/20 0.42
FGFR1 P11362 1/20 0.41
FLT1 P17948 1/20 0.41
KMT2A Q03164 1/20 0.41
HPGD P15428 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31404329 1.00 NUDT1 (0.59) NUDT1METAP1METAP2PDE5AAURKA
Water SCHEMBL31266989 0.77 NUDT1 (0.96) NUDT1METAP1METAP2PDE5AAURKA
Water SCHEMBL30578580 0.77 NUDT1 (0.96) NUDT1METAP1METAP2PDE5AAURKA
SCHEMBL861789 0.76 HPSE (0.52) NUDT1METAP1METAP2PDE5AHPSE
SCHEMBL5385517 0.76 NUDT1 (0.49) NUDT1METAP1METAP2PDE5ATP53
SCHEMBL29066590 0.75 LMNA (0.60) NUDT1PDE5AHPSEKDM4EFGFR1
SCHEMBL30413155 0.75 NUDT1 (1.00) NUDT1METAP1METAP2PDE5AAURKA
SCHEMBL42319 0.75 NUDT1 (1.00) NUDT1METAP1METAP2PDE5AAURKA
SCHEMBL1170747 0.74 METAP1 (0.72) NUDT1METAP1METAP2PDE5AAURKA
SCHEMBL3997802 0.74 PDE5A (0.50) NUDT1METAP1METAP2PDE5AAURKA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220380341-A1 INHIBITORS OF HIV-1 NEF FOR THE TREATMENT OF HIV DISEASE UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2022-12-01 US disclosed
WO-2020081856-A1 INHIBITORS OF HIV-1 NEF FOR THE TREATMENT OF HIV DISEASE UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2020-04-23 WO disclosed
EP-0646579-A1 Ketonic indane derivatives and heterocyclic analysis and their use in therapy LABORATOIRE INNOTHERA Société Anonyme (FR) 1995-04-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220380341-A1 INHIBITORS OF HIV-1 NEF FOR THE TREATMENT OF HIV DISEASE NAT1, CXCR4, HAX1 NUDT1 422/4885METAP1 1809/4885METAP2 3693/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.